key: cord-0749581-ouk9sho2
authors: Mamtani, M.; Athavale, A. M.; Abraham, M.; Vernik, J.; Amarah, A. R.; Ruiz, J. P.; Joshi, A. J.; Itteera, M.; Zhukovski, S. D.; Madaiah, R. P.; White, B. C.; Hart, P.; Kulkarni, H.
title: ASSOCIATION OF HYPERGLYCAEMIA WITH HOSPITAL MORTALITY IN NONDIABETIC COVID-19 PATIENTS: A COHORT STUDY
date: 2021-03-26
journal: Diabetes Metab
DOI: 10.1016/j.diabet.2021.101254
sha: 6f22ee99d3dd3e3b5db1051a72531994bda39134
doc_id: 749581
cord_uid: ouk9sho2

Objective Diabetes is a known risk factor for mortality in Coronavirus disease 2019 (COVID-19) patients. Our objective was to identify prevalence of hyperglycaemia in COVID-19 patients with and without prior diabetes and quantify its association with COVID-19 disease course. Research Design and Methods This observational cohort study included all consecutive COVID-19 patients admitted to John H Stroger Jr. Hospital, Chicago, IL from March 15, 2020 to May 3, 2020 and followed till May 15, 2020. The primary outcome was hospital mortality, and the studied predictor was hyperglycaemia [any blood glucose ≥ 7.78 mmol/L (140 mg/dL) during hospitalization]. Results Of the 403 COVID-19 patients studied, 51 (12.7%) died; 335 (83.1%) were discharged while 17 (4%) were still in hospital. Hyperglycaemia occurred in 228 (56.6%) patients; 83 of these hyperglycaemic patients (36.4%) had no prior history of diabetes. Compared to the reference group no-diabetes / no-hyperglycaemia patients the no-diabetes / hyperglycaemia patients showed higher mortality [1.8% versus 20.5%, adjusted odds ratio 21.94 (95% confidence interval 4.04-119.0), P < 0.001]; improved prediction of death (P = 0.01) and faster progression to death (P < 0.01). Hyperglycaemia within the first 24 and 48 hours was also significantly associated with mortality (odds ratio 2.15 and 3.31, respectively). Conclusions Hyperglycaemia without prior diabetes was common (20.6% of hospitalized COVID-19 patients) and was associated with an increased risk of and faster progression to death. Development of hyperglycaemia in COVID-19 patients who do not have diabetes is an early indicator of progressive disease.

The coronavirus disease 2019 (COVID- 19) pandemic has resulted in over 98 million cases and 2.1 million deaths globally [1] . Diabetes is associated with a higher mortality, need for intensive care, acute respiratory distress syndrome in COVID-19 disease [2] . Diabetes (HbA1C ≥ 6.5%) and/or uncontrolled hyperglycaemia (≥ 2 glucose measurements > 10.0 mmol/L (> 180 mg/dL)) are associated with poor outcomes in COVID-19 patients [3] . However, stress hyperglycaemia (defined as blood glucose values exceeding 7.78 mmol/L (140 mg/dL)) in the absence of diabetes is seen in severe acute illness [4] [5] [6] . Previous studies have shown that in critically ill patients, stress hyperglycaemia is associated with poor clinical outcomes during hospitalization [7] . Stress hyperglycaemia can prolong the length of hospital stay [8] -a parameter that is closely linked with poor outcomes in COVID-19 patients [9] . An excess of circulating proinflammatory cytokines (common in COVID-19 patients) is associated with the consequences of hyperglycaemia [10] . Sardu et al [11] showed that hyperglycaemia during hospitalization correlated with interleukin-6 and D-dimer concentrations in COVID-19 patients. However, the mechanistic basis and replicability of associations of hyperglycaemia in absence of diabetes with COVID-19 disease course remains understudied.

In this investigation, we focused on the potential of hyperglycaemia detected early during hospitalization of COVID-19 as an indicator of mortality. We hypothesized that hyperglycaemia even in the absence of diabetes may be associated with adverse outcomes in COVID-19 patients.

Here, we report the independent association of hyperglycaemia with clinical course in J o u r n a l P r e -p r o o f patients using a single-centre data of hospitalized COVID-19 patients from the United States of America.

This retrospective, hospital record-based study was conducted at John H. Stroger, Jr Hospital of Cook County, Chicago, IL. All COVID-19 patients admitted between March 15, 2020 and May 3, 2020 and followed till the censoring date of May 15, 2020 were included. Thus, follow-up of the cohort was done from the date of admission to the hospital to one of the following endpoints: in-hospital death; hospital discharge or censoring on the day the study ended (May 15, 2020). On the censoring day, 17 (4%) patients were still in hospital. COVID-19 was confirmed using the polymerase chain reaction for the RdRp and N genes. Clinical data of these patients was collected by chart reviews. The study was approved by the Institutional Review Board of the Cook County Health, Chicago, IL with waiver of informed consent.

The primary outcomes were hospital mortality and time to progress to mortality. Outcome ascertainment was censored on May 15, 2020. Patients still in hospital who did develop an outcome under consideration were censored for computation of length of stay and time-to-event analyses. Main predictor of interest was hyperglycaemia defined as at least one BG value ≥ 7.78 mmol/L (140 mg/dL) -a cut-off recommended as a treatment target in critically ill patients [12] and a definition of hyperglycaemia in non-critically ill hospitalized patients [13] . To examine the J o u r n a l P r e -p r o o f use of hyperglycaemia as an early predictor of adverse outcomes, we also considered occurrence of hyperglycaemia within the first 24 hours (HG24) and 48 hours (HG48) of admission. BG values were retrospectively derived from the database and represented a mixture of fasting and nonfasting measurements and venous and capillary sources. Detailed information collected on sociodemographics, presenting symptoms, comorbidities, laboratory investigations, history of medications and substance use from the electronic health records. Severity of illness at admission was quantified using the qSOFA score that combines information from respiratory rate, systolic blood pressure and mental status into a single metric [14] .

Descriptive statistics included mean ± standard deviation for continuous variables and number (%) for categorical variables. The time trends of BG values during hospitalization were examined using generalized estimating equations (GEE). The GEE models used Gaussian family function, identity link function and equal correlation structure. BG time trends were smoothed using cubic splines with a knot every day for the first 14 days of admission. The association of diabetes and hyperglycaemia with outcomes was tested for significance using the Pearson's chisquare test and the Kruskal-Wallis test as appropriate. The association with risk of mortality was quantified as odds ratios (OR) using multivariable stepwise logistic regression analyses with forward addition strategy and a retention criterion of 0.05. The forward addition strategy was used since it is robust to the number of predictors for a moderate size dataset and accounts for the potential collinearity among covariates without overfitting the data. We did not input missing data and the stepwise models described below have been run on participants without missing J o u r n a l P r e -p r o o f data. The first step of the forward addition strategy -included a total of 59 covariates -4 sociodemographic variables (age, gender, ethnicity and black race), 12 symptoms (cough, cough with sputum, nasal congestion, headache, fever, fever with chills, shortness of breath, nausea/vomiting, diarrhoea, myalgia, altered mental status and fatigue), 14 comorbidities (hypertension, diabetes, coronary artery disease, congestive heart failure, chronic obstructive pulmonary disease, asthma, other lung disease, chronic kidney disease, end-stage renal disease, chronic liver disease, cancer, ever smoker, alcohol consumption and qSOFA score) , 11 laboratory investigations (total white cell count, neutrophil count, lymphocyte count, platelet count, haemoglobin concentration, serum sodium, serum bicarbonates, serum creatinine, serum globulin, proteinuria, haematuria) 15 medications (insulin, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists, beta-blockers, other anti-hypertensive, statins, non-steroidal anti-inflammatory drugs, aspirin, vitamin D, hydroxychloroquine, azithromycin, rivaroxaban, chemotherapy and steroids) and 3 substance use variables (marijuana, cocaine and heroin). In the second step of this analysis, we added hyperglycaemia to the full model (total number of covariates 60). Lastly, to understand the association of hyperglycaemia with and without diabetes, we replaced the covariate hyperglycaemia with indicators for diabetes and hyperglycaemia groups and used the DM-/HGpatients as the reference group. Improvement in the prediction of the mortality using hyperglycaemia was also assessed by estimating the area under a receiver-operating characteristic curve (AUROC) from the fitted logistic regression models. Statistical significance for difference between two AUROCs was tested using the DeLong and DeLong test. To ensure robustness of the analyses conducted, we embarked upon some additional analyses. First, since J o u r n a l P r e -p r o o f some patients initially not identified as having diabetes could have been misclassified, we conducted sensitivity analyses by restricting the analyses to patients on whom HbA1C data was available; in this subset we reclassified patients with HbA1C ≥ 6.5% as diabetes. To arrive at robust estimates of standard errors and 95% confidence intervals, we conducted bootstrapping using the number of participants on whom HbA1C data was available and with 1000 replicates.

Second. We tested the hypothesis that the number of glucose measurements ordered till detection of hyperglycaemia is not a simple proxy measure of hyperglycaemia. Third, to ensure that the estimates of AUROC were unaffected by sample characteristics, we conducted 10-fold cross validation. For this, the folds were obtained a priori by shuffling the entire dataset and diving randomly into 10 equal parts. Ten-fold cross-validation proceeded by using each fold as the validation set and the remaining folds as the derivation set.

To test whether a continuous variable was associated with mortality in a linear fashion, we compared the likelihood ratio χ 2 statistic and the pseudo-R 2 of the untransformed covariate with a quadratic polynomial, cubic polynomial, log-transformed and square-root transformed variable as predictor. Further, we examined the strength of association of the quartiles of the untransformed variable with mortality and estimated the significance value of a linear trend using the Cochran-Armitage trend test. The association of early detection of hyperglycaemia with mortality was assessed by replacing the variable hyperglycaemia with hyperglycaemia during the first 24 hours (HG24) or 48 hours (HG48) in the multivariable stepwise logistic regression analyses described above.

To test the association of the study groups with the time to in-hospital mortality, we used Kaplan-Meier plots, logrank test and Cox proportional hazards regression to estimate the hazard J o u r n a l P r e -p r o o f ratios (HR). To test the independence of association from potential confounders, we used a forward addition, stepwise Cox regression variable selection strategy similar to the one used in logistic regression analyses explained above. Even though the study enrolled the patients from the time of admission, for the survival analyses, participants were considered to enter the cohort on the date and time of the first detection of hyperglycaemia; if hyperglycaemia was never detected then date and time of hospital admission was considered as the entry point. Exit from the cohort was as defined earlier.

All statistical analyses were conducted using Stata 12.0 software package (Stata Corp., College Station, TX). The statistical significance was assessed at a type I error rate of 0.05.

We included a total of 403 (out of 406 eligible, 99.3%) COVID-19 patients who were admitted to the study centre and had non-missing data for diabetes and other comorbidities. Clinical characteristics of the study participants are detailed in Table I . Majority of the patients were male (67.7%), of Hispanic/Latino ethnicity (54.8%) and Black/African American race (38.0%). Of the study participants, 97 (24.1%) patients needed ICU admission; 56 (13.9%) patients needed mechanical ventilation; and 51 (12.7%) patients died.

Hyperglycaemia was observed in 228 (56.6%) patients ( Figure 

In the first step of the forward addition, stepwise logistic regression analyses, higher neutrophil percentage, older age, insulin therapy (as outpatient), haematuria, high serum globulin at admission, low platelet count and nasal congestion significantly associated covariates retained in this final model (Table II, Step 1). Interestingly, as shown in Table S1 (see supplementary materials associated with this article on line) and Figure S1 We assessed the robustness of this finding in several ways. First, sensitivity analyses on patients with HbA1c data reaffirmed these results with a comparably high OR (13.0 Table S2 ; see supplementary materials associated with this article on line) and bootstrap CIs mostly above unity. Second, the first detection of hyperglycaemia was not influenced by the number of BG measurements ordered till that time point (adjusted OR 0.94, 95% CI 0.87 -1.03). Third, we conducted a 10-fold cross-validation of the final model (Table II, (Table S3 ; see supplementary materials associated with this article on line) showed a consistent prediction across folds (average 10-fold accuracy 0.75) implying that the model did not overfit the data. Together, these results indicated that our observation of the association between hyperglycaemia and mortality risk in hospitalized COVID-19 patients was robust to potential misclassification and indication biases.

To examine the clinical use of hyperglycaemia as a predictor of mortality, we investigated whether detection of hyperglycaemia early after admission can still provide a prognostic value. Table II , step 2 by replacing the variable hyperglycaemia with hyperglycaemia detected during the first 24 hours (HG24) or 48 hours (HG48). We found (Table S4; see supplementary materials associated with this article on line) that both HG24 and HG48 were significant and independent predictor of mortality (HG 24 -OR 2.15, 95% CI 1.00 -4.59, HG 48 OR -3.31, 95% CI 1.44 -7.62). Sensitivity analyses (Table S1 ; see supplementary materials associated with this article on line) in patients with HbA1c data suggested that while HG24 was marginally non-significant, HG48 was an independent predictor of mortality. Together, these results indicated that hyperglycaemia was an early predictor of the risk of mortality in the study cohort.

The Kaplan-Meier plot ( Figure 2B Figure 2B , within the group of COVID-19 patients without diabetes those with hyperglycaemia rapidly progressed to death significantly faster as compared to those without hyperglycaemia (logrank P < 0.01) but such a significant difference was not observed in patients with diabetes.

Analogous to the logistic regression analyses for association with risk of death, we next conducted stepwise Cox regression analyses to test the association with time to death. These results showed (Table III) that the variables retained in Step 1 mostly matched those in Step 1 of Table 2 with the exception of fatigue, dialysis and steroid use. In Step 2, hyperglycaemia was retained as the most significant predictor (HR 5.56, 95% CI 1.62 -19.0). Also, age, marijuana use and rivaroxaban medication were retained in the final model and dialysis was not retained. In

Step 3, we observed that as compared to the reference group of DM-/HG-, hyperglycaemia (with or without diabetes) progressed to death significantly rapidly (HR 7.58 95% CI 1.73 -33.1 and J o u r n a l P r e -p r o o f 8.86 95% CI 1.90 -41.4, respectively). Further, when we investigated the association of early hyperglycaemia with time to mortality using Cox proportional hazards regression, we found that the direction of association was consistent with the results of corresponding logistic regression analyses but statistical significance for the association of HG24 and HG48 with time to death was not observed (Table S5 ; see supplementary materials associated with this article on line).

The prevalence of hyperglycaemia in our study of hospitalized COVID-19 patients was 56.6% which is higher than the 38-40% prevalence reported in non-COVID-19 patients [15] . Our analyses have uncovered hospitalized nondiabetic COVID-19 patients with hyperglycaemia as a subgroup (20.6%) that is associated with a high risk of death and progress rapidly to death. Diabetes patients are a known high-risk group in COVID-19 disease [2, 16] . While our results support this view, they also imply that it may be more informative to focus on the glycaemic status as an indicator of the clinical course of COVID-19 patients. Focusing on hyperglycaemia, as shown by results in Table II, Table III prognosis. It is noteworthy that our definition of hyperglycaemia is inherently biased towards picking up hyperglycaemia early during disease.

We and others have previously demonstrated that the degree of hyperglycaemia in critically ill patients without diabetes plays a significant prognostic role in predicting hospital mortality [8, J o u r n a l P r e -p r o o f 17, 18] . Indeed, Max Harry Weil, father of critical care medicine, knew by 1973 that in critically ill patients, "Elevation of blood sugar reflects secretion of increased amounts of catecholamines from the adrenal medulla" [19] . Epinephrine-induced phosphorylation of the insulin receptor reduces its tyrosine kinase activity [20] and causes prompt and prolonged inhibition of pancreatic insulin secretion [21] . Thus, early appearance of hyperglycaemia in nondiabetic COVID-19 patients likely signals increased systemic stress.

We conjecture that hyperglycaemia may contribute to development of cytokine storm [11, 22, 23] and severe lung pathology in critically ill COVID-19 patients by promoting proinflammatory glycosylation of the Fc portion of IgG. A key characteristic that determines IgG pathogenicity is Fc glycosylation [24] . As discussed by Bermingham et al [25] , hyperglycaemia can drive production of diphosphate-N-acetylglucosamine, a substrate for glycosylation of IgG-Fc. Elevated HbA1c is associated with pro-inflammatory glycosylation of IgG-Fc in both Type 1 and Type 2 diabetics [26, 27] and predicts a more difficult course of COVID-19 [28] . Hoepel et al. [29] found increased Fc glycosylation in anti-Spike IgG from severely ill COVID-19 patients and went on to show that macrophages responded to these patients' Spike-IgG immune complexes by producing inflammatory cytokines. In an in vitro model with human macrophages, pulmonary artery endothelial cells, and platelets, these Spike-IgG immune complexes induced long-lasting endothelial disruption and platelet activation. Spike-IgG immune complexes without enhanced Fc glycosylation did not induce these pathophysiological responses, and specific blockade of the macrophage Fcγ2 receptor blocked the inflammatory response to enhanced Fc-glycosylated IgG-Spike immune complexes [29] . Similarly, Zlamal et al [30] have demonstrated platelets' Fcγ2- Platelet activation induced by enhanced Fc glycosylated immune complexes is consistent with platelet hyperactivity in severe COVID-19 patients [31] and autopsy histopathology identifying platelet-fibrin microthrombi in the lungs [32] . Excessive macrophage stimulation by enhanced Fcglycosylated immune complexes is consistent with the macrophage activation syndrome (MAS) often manifest in the laboratory values seen in severe COVID-19 [33] . The result is hypercoagulability with compromised micro perfusion, pulmonary endothelial fluid leakage, and severe respiratory distress syndrome that can result in death.

However, this prognostic role of hyperglycaemia varies by the primary cause of critical care such that primary diagnoses like trauma, coma and neurological diseases are especially prone to high likelihood of adverse outcomes associated with hyperglycaemia [8] . Our results need to be viewed in the light of the emerging literature on association of hyperglycaemia with COVID-19 prognosis. Studies have shown that pre-existing diabetes [2] , newly detected diabetes [34] , prediabetes [35] , uncontrolled hyperglycaemia (≥ 2 BG values of ≥ 10 mmol/L(180 mg /dl) [3] ) or fasting BG ≥ 7 mmol/L (≥ 126 mg/dL) [36] are significant determinants of COVID-19 prognosis.

Our study adds to these findings the observation that hyperglycaemia detected early after hospitalization in patients without a history of diabetes can also independently predict the disease course in COVID-19 patients. Notably, as posited by Sathish et al [37] , SARS-CoV-2 may directly injure the pancreatic β-cells, may impede insulin signalling pathways or activate the J o u r n a l P r e -p r o o f renin-angiotensin system and via a combination of these mechanisms may contribute to new onset diabetes. We do not have post-discharge follow-up data on the study subjects to evaluate whether the hyperglycaemia detected during current hospitalization persisted after discharge, however, there remains a distinct possibility that the nondiabetic hyperglycaemia observed during a COVID-19 hospitalization may be a harbinger of new or unmasked diabetes.

Three other incidental findings in this study merit a mention. First, haematuria was found to be significantly associated with the risk of mortality in the logistic regression model. There is burgeoning evidence to support the association of haematuria, proteinuria and acute kidney injury (AKI) during COVID-19 disease and these parameters are considered to be early indicators of the renal involvement in COVID-19 [38] . The observed independent association of haematuria with mortality in this study, thus raises the possibility of kidney involvement. Whether this association is further accentuated by the presence of diabetes and/or hyperglycaemia needs to be investigated in future studies. Second, we found that differential neutrophil count remained a significantly associated covariate across all models. Several other studies have demonstrated the prognostic utility of relative or absolute neutrophilia in COVID-19 [39] . Third, our study found that high initial platelet count was associated with a reduced risk of mortality -a finding that concurs with other observations [40] . Thus, our results concur with most of the other haematological associations with in-hospital mortaliHG24ty in COVID-19 patients, but additionally reports the association of diabetic as well as nondiabetic hyperglycaemia even after accounting for known haematological associations. Notably, the prevalence of other factors J o u r n a l P r e -p r o o f retained in final models shown in Tables II and III was low and thus resulted in wide confidence intervals that need to be evaluated in larger samples in future studies.

Our study has some limitations. First, this is a retrospective, observational study of hospitalized COVID-19 patients and is thus prone to all the limitations of observational studies.

For instance, causative association cannot be established from our results. While our analyses attempted to ensure that hyperglycaemia preceded the outcomes of interest, the possibility of a temporal bias cannot be refuted. Second, our study does not include any practice changes based on hyperglycaemia detection. However, our results suggest that a closer clinical scrutiny of COVID-19 patients based on glycaemic status may provide additional insights into their clinical course. Studies in future need to specifically address these hypotheses. Third, although we have provided a coherent model of the pathophysiology, whether hyperglycaemia in COVID-19 patients is consequential or coincidental to disease biology is currently unknown and cannot be surmised from our results. Studies are needed to specifically understand the biology of hyperglycaemia in COVID-19 patients. Fourth, since the BG data were retrospectively derived from the source of blood sample, its relation to fasting status remains unknown in this study. This heterogeneity of BG sampling could have biased our OR estimates. Despite this potential measured and unmeasured confounding, our results from sensitivity analyses indicate that our interpretations are likely to have been minimally influenced by confounding due to BG sampling.

Fifth, the likelihood of undiagnosed diabetes at admission was 4% and 10% in the nodiabetes/no-hyperglycaemia and no-diabetes/hyperglycaemia groups, respectively. We evaluated, through sensitivity analyses, the influence of this misclassification on our interpretations. While the sensitivity analyses demonstrated the robustness of our inferences, larger multicentric studies are needed before the findings can be generalized. Sixth, information on neither the duration of diabetes nor the duration and dose of antidiabetic medication was available. In the same vein, it should be noted that glucose lowering agents such as metformin have been shown to influence outcomes in COVID-19 patients [41, 42] . However, none of the admitted COVID-19 patients received any glucose lowering drug other than insulin which was accounted for in our analyses. Our study represents the clinical practice during very early stages of the pandemic when clear protocols for dysglycaemic COVID-19 patients were not in place.

Whether development and implementation of such protocols can improve COVID-19 outcomes cannot be directly answered by our study and should be evaluated in future studies. Seventh, arguably drugs such as dexamethasone that are used in the management of respiratory distress can directly inflate blood glucose levels and may masquerade as hyperglycaemia. During the very early stages of the pandemic that our study data captures, corticosteroids were not commonly used. Indeed, in our dataset only three patients had received steroids during index hospitalization. Therefore, we believe that the potential influence of glucose-altering drugs on our inferences would be minimal.

Nevertheless, we have observed the appearance of hyperglycaemia in nondiabetic COVID-19 patients who are much more likely to progress to severe disease. We suggest this is an early marker of a stress response that results in amplification of the pathophysiology outlined above. Close and perhaps continuous monitoring of blood glucose in hospitalized COVID-19 patients could provide clinicians with early recognition of this risk. Hyperglycaemia as defined in this study is mostly inclusive of and incremental to known diabetes status both in terms of prevalence and its association with mortality. Thus, presence of hyperglycaemia can enable early 

Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia -A systematic review, meta-analysis, and meta-regression

Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States

New-onset diabetes after acute and critical illness: a systematic review

Endocrine responses to critical illness: novel insights and therapeutic implications

Stress-induced hyperglycaemia

A systematic scoping review on the consequences of stress-related hyperglycaemia

Degree of hyperglycemia independently associates with hospital mortality and length of stay in critically ill, nondiabetic patients: Results from the ANZICS CORE binational registry

Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal

Mechanism of inflammatory response in associated comorbidities in COVID-19

Outcomes in patients with hyperglycemia affected by covid-19: can we do more on glycemic control?

Inpatient hyperglycemia management: A practical review for primary medical and surgical teams

Glucose Management in hospitalized patients

Prognostic accuracy of sepsis-3 criteria for in-hospital mortality among patients with suspected infection presenting to the emergency department

Management of diabetes and hyperglycemia in hospitalized patients

Prognostic factors in patients with diabetes hospitalized for COVID-19: Findings from the CORONADO study and other recent reports

Is intensive glucose control bad for critically ill patients? A systematic review and meta-analysis

Individualizing glycemic control in the critically ill

Treatment of shock caused by bacterial infections

Regulation of insulin receptor kinase by multisite phosphorylation

Galanin and epinephrine act on distinct receptors to inhibit insulin release by the same mechanisms including an increase in K+ permeability of the B-cell membrane

A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses

COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs

The Immunoregulatory Roles of Antibody Glycosylation

N-Glycan Profile and Kidney Disease in Type 1 Diabetes

Calcitonin receptor nglycosylation enhances peptide hormone affinity by controlling receptor dynamics

Glycomics for type 2 diabetes biomarker discovery: promise of immunoglobulin G subclass-specific fragment crystallizable n-glycosylation in the Uyghur population

Glycosylated hemoglobin is associated with systemic inflammation, hypercoagulability, and prognosis of COVID-19 patients

Anti-SARS-CoV-2 IgG from severely ill COVID-19 patients promotes macrophage hyper-inflammatory responses

cAMP prevents antibodymediated thrombus formation in COVID-19. medRxiv : the preprint server for health sciences 2020

Platelet gene expression and function in patients with COVID-19

Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study

Macrophage activation syndrome and COVID-19

Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID-19

Impaired glucose metabolism in patients with diabetes, prediabetes, and obesity is associated with severe COVID

Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre retrospective study

Potential metabolic and inflammatory pathways between COVID-19 and new-onset diabetes

Association of acute kidney injury with the severity and mortality of SARS-CoV-2 infection: A meta-analysis

Predicting disease severity and outcome in COVID-19 patients: a review of multiple biomarkers

Characteristics of peripheral blood differential counts in hospitalized patients with COVID-19

Metformin and COVID-19: From cellular mechanisms to reduced mortality

Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19

L -Litre, g/L -grams per Litre, % -percentage, μg/L -microgram per Litre, mEq/L -milliequivalent per Litre, mmol/L -millimole per Litre, mg/dL -milligram per decilitre, μmol/L -micromole per Litre, g/L -grams per Litre, U/L -units per Litre, IU/L -international units per Litre, mg/L -milligram per Litre

Supplementary materials ( Fig. S1 and Tables S1-S2-S3-S4) associated with this article can be found at http://www.scincedirect.com at doi . . .